参考文献/References:
[1]Al-Rubeaan K,Youssef AM,Subhani SN,et al.Diabetic nephropathy and its risk factors in a society with a type 2 diabetes epidemic:a Saudi National Diabetes Registry-based study[J].PLoS One,2014,9(2):e88956.[2]丁素英,刘东伟,安璐,等.郑州市体检人群慢性肾脏病危险因素分析[J].郑州大学学报(医学版),2016,51(6):787-791.[3]王惠珍,文枫,王文健.非编码RNA参与糖尿病肾病发病的机制及其诊疗价值[J].中华肾脏病杂志,2016,32(9):708-712.[4]努尔斯曼古丽·奥斯曼,焦谊,梁小弟,等.维吾尔族糖尿病肾病患者血清微小RNA的表达及其与糖尿病肾病的相关性[J].中华糖尿病杂志,2017,9(4):231-236.[5]陈桐,范秋灵,崔靖彬,等.糖尿病和糖尿病肾病患者血清lncRNAGAS5/miR-21的诊断效能[J].中华肾脏病杂志,2017, 33(12):906-913.[6]李鑫,范秋灵,汪旭,等.2型糖尿病和糖尿病肾病患者血清微小RNA-148b-3p的水平变化及意义[J].中华肾脏病杂志,2018,34(5):348-354.[7]McClelland AD,Herman-Edelstein M,Komers R,et al.miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7[J].Clin Sci.2011,29(12):1237-1249.[8]Wang J,Duan L,Tian L,et al.Serum miR-21 may be a Potential Diagnostic Biomarker for Diabetic Nephropathy[J].Exp Clin Endocrinol Diabetes,2016,124(7):417-423. [9]Senanayake U,Das S,Vesely P,et al.miR-192,miR-194,miR-215,miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms[J].Carcinogenesis,2012,33(5):1014-1021.[10]Ma X,Lu C,Lv C,et al.The Expression of miR-192 and Its Significance in Diabetic Nephropathy Patients with Different Urine Albumin Creatinine Ratio[J].J Diabetes Res,2016(2016):6789402. [11]Peng H,Zhong M,Zhao W,et al.Urinary miR-29 correlates with albuminuria and carotid intima-media thickness in type 2 diabetes patients[J].PLoS One,2013,8(12):e82607.[12]Delic D,Eisele C,Schmid R,et al.Urinary Exosomal miRNA Signature in Type II Diabetic Nephropathy Patients[J].PLoS One,2016,11(3):e0150154.[13]季振中,胡正国,徐焱成.糖尿病肾病患者血清miRNA377的表达及其对SMAD信号通路调控作用[J].重庆医学,2016, 45(27):3824-3826.[14]梁田田,王惠珍,柒春芳,等.糖尿病和糖尿病肾病小鼠肾组织中长链非编码RNA的差异表达[J].中华肾脏病杂志,2019,35(2):127-135.[15]张攀扬,孙艳,彭睿,等.长链非编码RNARpph1对高糖培养的肾小球系膜细胞验证因子表达的影响[J].第三军医大学学报,2019,41(1):33-40.[16]Long J,Badal SS,Ye Z,et al.Long noncoding RNA Tug1 regulates mitochondrial bioenergetics in diabetic nephropathy[J].J Clin Invest,2016,126(11):4205-4218.[17]Hu M,Rong W,Li X,et al.LncRNA MALAT1 is dysregulated in diabetic nephropathy and involved in high glucose-induced podocyte injury via its interplay with b-catenin[J].J Cell Mol Med,2017,21(11):2732-2747.[18]Zhang M,Gu H,Chen J,et al.Involvement of long noncoding RNA MALAT1 in the pathogenesis of diabetic cardiomyopathy[J].Int J Cardiol,2016(202):753-755. [19]Duan LJ,Ding M,Hou LJ,et al.Long noncoding RNA TUG1 alleviates extracellular matrix accumulation via mediating microRNA-377 targeting of PPARγ in diabetic nephropathy[J].Biochem Biophys Res Commun,2017,484(3):598-604.[20]Yan B,Yao J,Liu JY,et al.lncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA[J].Circ Res,2015,116(7):1143-1156. [21]Wang M,Yao D,Wang S,et al.Long non-coding RNA ENSMUST00000147869 protects mesangial cells from proliferation and fibrosis induced by diabetic nephropathy[J].Endocrine,2016,54(1):81-92.[22]Lucrecia AM,Distefano JK,Lee LTO.Functional Characterization of the Plasmacytoma Variant Translocation 1 Gene(PVT1)in Diabetic Nephropathy[J].PLoS One,2011,6(4):e18671.[23]马红霞,殷万元,王玭.反义线粒体非编码RNA-2在高糖环境下的肾小球系膜细胞中的表达及作用机制[J].海南医学院学报,2018,24(14):1307-1310.[24]Li X,Zhao Z,Gao C,et al.The Diagnostic Value of Whole Blood lncRNA ENST00000550337.1 for Pre-Diabetes and Type 2 Diabetes Mellitus[J].Exp Clin Endocrinol Diabetes,2017,125(6):377-383.[25]Kato M,Wang M,Chen Z,et al.An endoplasmic reticulum stress-regulated lncRNA hosting a microRNA megacluster induces early features of diabetic nephropathy[J].Nat Commun,2016(7):12864.[26]陈桐,范秋灵,崔靖彬,等.糖尿病和糖尿病肾病患者血清LncRNAGAS5/miR-21的诊断效能[J].中华肾脏病杂志,2017,33(12):906-913.[27]吕小萌,范秋灵,汪旭,等.糖尿病和糖尿病肾病患者循环IncRNA表达谱的分析[J].中国实用内科杂志,2017,37(3):221-226.
相似文献/References:
[1]尹晓华,刘重元,黄 琳,等.胃癌中lncRNAs的研究进展[J].医学信息,2018,31(03):10.[doi:10.3969/j.issn.1006-1959.2018.03.004]
YIN Xiao-hua,LIU Zhong-yuan,HUANG Lin,et al.Research Progress of lncRNAs in Gastric Cancer[J].Medical Information,2018,31(21):10.[doi:10.3969/j.issn.1006-1959.2018.03.004]
[2]陈淑雯.肾衰宁联合科素亚治疗早期糖尿病肾病的临床观察[J].医学信息,2018,31(05):20.[doi:10.3969/j.issn.1006-1959.2018.05.007]
CHEN Shu-wen.Clinical Observation on Early Diabetic Nephropathy Treated by Shenshuaining Combined with Kosu[J].Medical Information,2018,31(21):20.[doi:10.3969/j.issn.1006-1959.2018.05.007]
[3]何丽杰.中西医治疗糖尿病肾病的临床效果分析[J].医学信息,2018,31(10):149.[doi:10.3969/j.issn.1006-1959.2018.10.051]
HE Li-jie.Clinical Effect Analysis of Diabetic Nephropathy Treated by Chinese and Western Medicine[J].Medical Information,2018,31(21):149.[doi:10.3969/j.issn.1006-1959.2018.10.051]
[4]刘 坤,陈德春.基于生信学方法分析GSDM基因家族在膀胱癌的表达及临床意义[J].医学信息,2022,35(10):14.[doi:10.3969/j.issn.1006-1959.2022.10.003]
LIU Kun,CHEN De-chun.Expression and Clinical Significance of GSDM Gene Family in Bladder Cancer Based on Bioinformatics Analysis[J].Medical Information,2022,35(21):14.[doi:10.3969/j.issn.1006-1959.2022.10.003]
[5]陶碧君,刘建德,王玉洲.LncRNA FOXD3-AS1在恶性肿瘤中的表达、功能及作用机制[J].医学信息,2022,35(10):51.[doi:10.3969/j.issn.1006-1959.2022.10.012]
TAO Bi-jun,LIU Jian-de,WANG Yu-zhou.Expression, Function and Mechanism of LncRNA FOXD3-AS1 in Malignant Tumors[J].Medical Information,2022,35(21):51.[doi:10.3969/j.issn.1006-1959.2022.10.012]
[6]贺 伟,高 峰.24 h尿微量白蛋白、血清胱抑素C水平与血清肌酐、尿素水平在2型糖尿病肾病早期诊断的意义[J].医学信息,2018,31(11):151.[doi:10.3969/j.issn.1006-1959.2018.11.049]
HE Wei,GAO Feng.The Significance of 24 h Urinary Microalbumin,Serum Cystatin C and Serum Creatinine and Urea Levels in the Early Diagnosis of Type 2 Diabetic Nephropathy[J].Medical Information,2018,31(21):151.[doi:10.3969/j.issn.1006-1959.2018.11.049]
[7]黄秋菊.胱抑素C及脂蛋白α在早期糖尿病肾病诊断中的价值研究[J].医学信息,2018,31(14):57.[doi:10.3969/j.issn.1006-1959.2018.14.018]
HUANG Qiu-ju.The Value of Cystatin C and Lipoprotein α in the Diagnosis of Early Diabetic Nephropathy[J].Medical Information,2018,31(21):57.[doi:10.3969/j.issn.1006-1959.2018.14.018]
[8]陆新虹,温玉洁,胡 欣,等.α-硫辛酸对2型糖尿病肾病患者
血清内脂素的影响研究[J].医学信息,2018,31(14):60.[doi:10.3969/j.issn.1006-1959.2018.14.019]
LU Xin-hong,WEN Yu-jie,HU Xin,et al.Effect of α-lipoic Acid on Serum Visfatin in Patients with
Type 2 Diabetic Nephropathy[J].Medical Information,2018,31(21):60.[doi:10.3969/j.issn.1006-1959.2018.14.019]
[9]肖学秀.益气活血汤联合西药治疗早期糖尿病肾病的临床观察[J].医学信息,2019,32(02):166.[doi:10.3969/j.issn.1006-1959.2019.02.051]
XIAO Xue-xiu.Clinical Observation of Yiqi Huoxue Decoction Combined with Western Medicine in Treating Earlyn Diabetic Nephropathy[J].Medical Information,2019,32(21):166.[doi:10.3969/j.issn.1006-1959.2019.02.051]
[10]郑小鹏,辛 华.糖尿病肾病研究进展[J].医学信息,2018,31(16):26.[doi:10.3969/j.issn.1006-1959.2018.16.008]
ZHENG Xiao-peng,XIN Hua.Progress in the Study of Diabetic Nephropathy[J].Medical Information,2018,31(21):26.[doi:10.3969/j.issn.1006-1959.2018.16.008]
[11]余世纪,谢勇丽,苏晓清.血清VDBP、IL-8、sTWEAK与尿VDBP早期诊断糖尿病肾病的价值[J].医学信息,2019,32(09):38.[doi:10.3969/j.issn.1006-1959.2019.09.013]
YU Shi-ji,XIE Yong-li,SU Xiao-qing.The Value of Serum VDBP,IL-8,sTWEAK and Urine VDBP in Early Diagnosis of Diabetic Nephropathy[J].Medical Information,2019,32(21):38.[doi:10.3969/j.issn.1006-1959.2019.09.013]
[12]黄桢宇,李 烨,朱彩凤.糖尿病肾病生物标志物的全球趋势与热点[J].医学信息,2026,39(06):66.[doi:10.3969/j.issn.1006-1959.2026.06.011]
HUANG Zhenyu,LI Ye,ZHU Caifeng.Global Trends and Hotspots of Biomarkers for Diabetic Nephropathy[J].Medical Information,2026,39(21):66.[doi:10.3969/j.issn.1006-1959.2026.06.011]